CymaBay Therapeutics

Ticker CBAY

Exchange NASDAQ More
Industry Biotechnology More
Sector Healthcare More

11-50 Employees
Based in Newark, California

CymaBay Therapeutics, Inc. (CBAY) is a clinical-stage biopharmaceutical company developing therapies to treat metabolic diseases with high unmet medical need, including serious rare and orphan disorders. MBX-8025 is a potent, selective, orally active PPARδ agonist.

Visit website

Social Media Links

REPORT RATINGS

4.8 / 5.0 (118)

CymaBay Therapeutics reports have an aggregate usefulness score of 4.8 based on 118 reviews.

CymaBay Therapeutics

Most Recent Annual Report

MOST RECENT 2023 Annual Report and Form 10K

View PDF View Form 10K (HTML)

CymaBay Therapeutics does not currently have any hardcopy reports on AnnualReports.com. Click the button below to request a report when hardcopies become available.

Please fill out the form below and click "Place Order" to complete your order.